GSK Acquires RAPT Therapeutics for $2.2 Billion to Develop New Food Allergy Treatment

GSK purchases RAPT Therapeutics for $2.2B, gaining ozureprubart - a promising food allergy treatment requiring injections every 12 weeks instead of every 2 weeks.